Careers
Contact Us

Company
Pipeline
Disease States
Science
Investors

Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility

Posted January 7, 2019 by CognitionDev

filed under: Nasdaq

In the News

Apr 15, 2019

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation

Click to view full release

Mar 27, 2019

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder

Click to view full release

Mar 14, 2019

Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Click to view full release

See All News

© 2019 Axsome Therapeutics, Inc. All rights reserved. 200 Broadway, 3rd Floor, New York, NY 10038 info@axsome.com

This modal has no inner div